| 董亚茹,薛秀云,张 琳,史利利,党晓燕.依达拉奉联合克林澳对急性脑梗死患者血清MMP-3、MMP-9、TIMP-1、EPCs的影响及疗效观察[J].,2018,(23):4539-4543 |
| 依达拉奉联合克林澳对急性脑梗死患者血清MMP-3、MMP-9、TIMP-1、EPCs的影响及疗效观察 |
| To Observe the Effect of Edaravone Combined with Cinepazide Maleate on Patients with Acute Cerebral Infarction Serum MMP-3, MMP-9, TIMP-1, EPCs |
| 投稿时间：2018-04-27 修订日期：2018-05-21 |
| DOI：10.13241/j.cnki.pmb.2018.23.033 |
| 中文关键词: 依达拉奉 克林澳 急性脑梗死 MMP-3 MMP-9 TIMP-1 EPCs |
| 英文关键词: Edaravone Cinepazide maleate Acute cerebral infarction MMP-3 MMP-9 TIMP-1 EPCs |
| 基金项目:陕西省教育厅科学研究计划项目(14JK1614) |
|
| 摘要点击次数: 316 |
| 全文下载次数: 117 |
| 中文摘要: |
| 摘要 目的：研究依达拉奉联合克林澳对急性脑梗死患者血清MMP-3（基质金属蛋白酶-3）、MMP-9（基质金属蛋白酶-9）、TIMP-1（组织基质金属蛋白酶抑制剂1）、EPCs（内皮祖细胞）的影响及疗效观察。方法：选取我院收治的114例急性脑梗死患者，按照随机数表法分为联合治疗组（n=57）和单独治疗组（n=57）。单独治疗组仅应用依达拉奉治疗，联合治疗组则联合克林澳治疗。观察并比较两组患者临床治疗效果、NIHSS（美国国立卫生研究院卒中量表）评分变化情况、实验室指标水平变化情况、血脂水平变化情况以及不良反应发生情况。结果：治疗后，联合治疗组基本痊愈和显著进步的患者达到49例，其总有效率为85.96%，而单独治疗组基本痊愈和显著进步的患者仅为39例，其总有效率为68.42%，两组比较差异显著（P<0.05）。治疗14 d和28 d后，患者的评分均较治疗前有明显下降，同时，联合治疗组下降水平明显优于单独治疗组（P<0.05）。两组患者MMP3和MMP9水平较治疗前显著下降，而TIMP-1和EPCs水平则明显上升，且联合治疗组MMP3和MMP9水平下降情况和TIMP-1和EPCs水平上升情况均明显优于单独治疗组（P<0.05）。治疗14 d和28 d后，患者血脂各指标水平均较前一次测量有明显下降，且单独治疗组较联合治疗组下降更为明显（P<0.05）。联合治疗组不良反应发生率为5.26%；单独治疗组不良反应发生率为10.53%，不良反应发生率比较无统计学意义（P>0.05）。结论：依达拉奉联合克林澳应用于治疗急性脑梗死患者疗效确切，有效改善血清MMP-3、MMP-9、TIMP-1、EPCs以及患者血脂异常情况，促进血管新生，保护患者脑组织。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect of edaravone combined with cinepazide maleate on patients with acute cerebral infarction serum MMP-3, MMP-9, TIMP-1, EPCs. Methods: 114 cases with acute cerebral infarction were researched, according to the random number table they were divided into combined treatment group(n=57) and the single treatment group(n=57). The single treatment group was only treated with edaravone, and the combined treatment group was treated with edaravone and cinepazide malete. They were compared with clinical treatment effect, NIHSS score change, laboratory index level change, blood lipid level change and adverse reactions. Results: After treatment, combined treatment group cured and significantly improved patients reached 49 cases, the total effective rate was 85.96%, and the single treatment group cured and significant progress in patients with only 39 cases, the total effective rate was 68.42%, there was significant difference between two groups (P<0.05). After the treatment of 14 d and 28 d, the scores of patients were significantly lower than those before treatment, while the level of decrease in the combined treatment group was better than that in the single treatment group(P<0.05). Two groups of patients with MMP3 and MMP9 levels decreased significantly, while TIMP-1 and EPCs levels increased significantly, and the combined treatment group MMP3 and MMP9 decreased and TIMP-1 and EPCs levels were significantly better than the single treatment group(P<0.05). After treatment of 14 d and 28 d, the indexes of blood lipid in patients decreased significantly compared with the previous measurement, and the decrease in the individual treatment group was more obvious than that in the combined treatment group(P<0.05). The adverse reaction rate was 5.26% in the combined treatment group, the adverse reaction rate in the single treatment group was 10.53%, and the adverse reaction rate was not statistically significant(P>0.05). Conclusion: Edaravone combined with cinepazide maleate used in the treatment of patients with acute cerebral infarction is effective, effectively improve the serum levels of MMP-3, MMP-9, TIMP-1, EPCs and blood lipid abnormalities, promote angiogenesis, protect the brain tissue of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
